Min & Kim, Diabetes Metab J, 2022 The Next Generation of Metabolic Medicine The efficacy and safety of Tirzepatide are supported by the extensive SURPASS and SURMOUNT clinical trial programs, heralding a new era in weight management
Neurotherapeutics 17 , 243251 (2020)
2 The administration of GLP-1 agonists (GLP-1As) can sufficiently replace the action of incretins and lower glucose levels
It belongs to a class of medications known as dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists
Data availability The study was approved by the Mass General Brigham Institutional Review Board
This page goes deep into the mechanics of the dual GIP/GLP-1 agonist, explains why tirzepatide carries the highest risk of the entire drug class, and shows the clear difference between Mounjaro (diabetes) and Zepbound (obesity)